Compare ETJ & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETJ | LENZ |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 586.2M | 609.5M |
| IPO Year | 2007 | 2021 |
| Metric | ETJ | LENZ |
|---|---|---|
| Price | $8.70 | $12.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $56.25 |
| AVG Volume (30 Days) | 157.1K | ★ 854.3K |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $157.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.70 | $11.48 |
| 52 Week High | $9.12 | $50.19 |
| Indicator | ETJ | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 28.28 |
| Support Level | $8.67 | N/A |
| Resistance Level | $8.98 | $30.24 |
| Average True Range (ATR) | 0.08 | 0.87 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 38.46 | 9.95 |
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.